6,065 reports of this reaction
5.2% of all LEVETIRACETAM IN SODIUM CHLORIDE reports
#3 most reported adverse reaction
OFF LABEL USE is the #3 most commonly reported adverse reaction for LEVETIRACETAM IN SODIUM CHLORIDE, manufactured by Actavis Pharma, Inc.. There are 6,065 FDA adverse event reports linking LEVETIRACETAM IN SODIUM CHLORIDE to OFF LABEL USE. This represents approximately 5.2% of all 117,343 adverse event reports for this drug.
Patients taking LEVETIRACETAM IN SODIUM CHLORIDE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among LEVETIRACETAM IN SODIUM CHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for LEVETIRACETAM IN SODIUM CHLORIDE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 6,065 FDA reports for LEVETIRACETAM IN SODIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 5.2% of all adverse event reports for LEVETIRACETAM IN SODIUM CHLORIDE, making it one of the most commonly reported side effect.
If you experience off label use while taking LEVETIRACETAM IN SODIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.